A study testing whether a new weekly shot from Biomed Industries, tirzepatide, can help with weight.

Who can join

Adults 19 to 80, have obesity or are overweight, BMI 27+.

What you take

tirzepatide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.

How long it lasts

The study runs about 16 months.

What you get

The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.

What this study is for

Full study title: Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese.

Primary condition: Obesity and Overweight.

Who can join, in detail

Key inclusion criteria

• A written informed consent must be obtained before any study-related assessments are performed.
• Men and women between 18 and 80 years, inclusive; women of child-bearing potential (defined as those who are not post-menopausal or post-surgical sterilization) must meet both of the following criteria:
• Two negative pregnancy tests (at screening and at randomization, prior to dosing)
• Use of intrauterine device, from at least 3 months before the baseline visit through at least 4 months after the last dose of NA-931/placebo oral, and an additional contraceptive (barrier) method from screening through at least 4 months after the last dose of NA-931/placebo oral.
• Body mass index (BMI) >= 30 or BMI >= 27 with one or more obesity-associated comorbidities (e.g., hypertension, insulin resistance, sleep apnea, or dyslipidemia)

Key exclusion criteria

• • History of, or known hypersensitivity to, monoclonal antibody drugs or a contraindication to Tirzepatide (Zepbound or Mounjaro)
• Use of other investigational drugs at the time of enrollment or within 30 days or 5 half-lives of enrollment, whichever is longer, or longer if required by local regulations
• Treatment with any medication for the indication of obesity within the past 30 days before screening
• Diagnosis of diabetes requiring current use of any antidiabetic drug or HbA1c >= 6.5% Note: Metabolic syndrome is not an exclusion, even if managed with an anti-diabetic drug such as metformin or an SGLT2 inhibitor. A diagnosis of prediabetes or impaired glucose tolerance managed exclusively with non-pharmacologic approaches (e.g., diet and exercise) is not an exclusion.
• Any chronic infections likely to interfere with study conduct or interpretation such as hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency virus (HIV). History of hepatitis A or hepatitis C successfully treated is not exclusionary. Active COVID-19 infection.

Where this study is enrolling

This trial has 8 US sites across 4 states. Contact the site coordinator directly to start the screening process.

Timeline

Started enrolling: 2026-08-15. Expected completion: 2027-12-15. Last updated on ClinicalTrials.gov: 2026-03-27.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Other GLP-1 clinical trials

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact